Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 2 , Pages 133-138 , March 2012

Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: A pilot study

  • Michael Perrotti, M.D.

      Affiliations

    • Urologic Oncology Service, St. Peter's Cancer Care Center, Albany, NY 12208, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-518-438-1019; fax: +1-518-438-0981
    • ,
  • Ritu Jain, Ph.D.

      Affiliations

    • SUNY Research Foundation, University at Albany, Albany, NY 12208, USA
    • ,
  • Linda M. Abriel, R.N., A.N.P.

      Affiliations

    • Urologic Oncology Service, St. Peter's Cancer Care Center, Albany, NY 12208, USA
    • ,
  • Timothy E. Baroni, Ph.D.

      Affiliations

    • SUNY Research Foundation, University at Albany, Albany, NY 12208, USA
    • ,
  • Amy B. Corbett, Ph.D.

      Affiliations

    • SUNY Cobleskill, State University of New York, Cobleskill, NY 12043, USA
    • ,
  • Scott A. Tenenbaum, Ph.D.

      Affiliations

    • College of Nanoscale Science and Engineering, University at Albany-SUNY, Albany, NY 12208, USA

Received 26 October 2009 ,Revised 16 January 2010 ,Accepted 17 January 2010.

References 

  1. Jemel A , Siegel R , Ward E , et al.  Cancer statistics, 2009 . CA Cancer J Clin . 2009;59:225–249
  2. Byers T , Barrera E , Fontham ET , et al.  A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015 . Cancer . 2006;107:396–405
  3. Cetin K, Beebe-Dimmer JL, Fryzek JP, et al. Recent time trends in the epidemiology of stage IV prostate cancer in the United States: Analysis of data from the surveillance, epidemiology, and end results program. J Urol, in press.
  4. Moul JW . Prostate specific antigen only progression of prostate cancer . J Urol . 2000;163:1632–1642
  5. Seitz C , Remzi M , Djavan B . Immediate treatment after PSA progression . European Urology Supplements . 2005;4:28–42
  6. Freedland SJ , Moul JW . Prostate specific antigen recurrence after definitive therapy . J Urol . 2007;177:1985–1991
  7. Macdonald OK , D'Amico AV , Sadetsky N , et al.  Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: From the CapSURE database . Urol Oncol . 2008;26:271–275
  8. Stephenson AJ , Scardino PT , Kattan MW , et al.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy . J Clin Oncol . 2007;25:2035–2041
  9. Bushkirk SJ , Pisanksy TM , Schild SE , et al.  Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system . J Urol . 2006;176:985–990
  10. Sartor O, McLeod DG, Halabi S, et al. The COMPARE registry: Design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology, in press.
  11. Keating NL , O'Malley AJ , Smith MR . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer . J Clin Oncol . 2006;24:4448–4456
  12. Loblaw DA , Virgo KS , Nam R , et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 Update of an American Society of Clinical Oncology practice guideline . J Clin Oncol . 2007;25:1596–1605
  13. Xu Y , Dalrymple SL , Becker RE , et al.  Pharmacologic basis for the enhanced efficacy of dutasteride against prostate cancers . Clin Cancer Res . 2006;12:4072–4079
  14. Festuccia C , Gravina GL , Muzi P , et al.  Effects of dutasteride on prostate carcinoma primary cultures: A comparative study with finasteride and MK386 . J Urol . 2008;180:367–372
  15. Titus MA , Gregory CW , Ford OH , et al.  Steroid 5-α-reductase isoenzymes I and II in recurrent prostate cancer . Clin Cancer Res . 2005;11:4365–4371
  16. Iczkowski KA , Qiu J , Qian J , et al.  The dual 5-α-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate . Urology . 2005;65:76–82
  17. Roehrborn CG , Siami P , Barkin J , et al.  The effects of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-Year results form the combat study . J Urol . 2008;179:616–621
  18. Lange PH , Ercole CJ , Lightner DJ , et al.  The value of serum prostate specific antigen determination before and after radical prostatectomy . J Urol . 1989;141–147
  19. Amling CL , Bergstralh EJ , Blute ML , et al.  Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? . J Urol . 2001;65:1146–1151
  20. Roach M , Hanks G , Thames H , et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference . Int J Radiat Oncol Biol Phys . 2006;65:965–974
  21. Arlen PH , Bianco F , Dahut WL , et al.  Prostate-specific antigen working group's guidelines on PSA doubling time . J Urol . 2008;179:2181–2186
  22. Memorial Sloan-Kettering Cancer Center cancer information: Prostate nomogram . http://www.mskcc.org/mskcc/html/10088.cfm Accessed December, 2009
  23. Scher HI , Eisenberger M , D'Amico AV , et al.  Eligibility and outcomes reporting guidelines for clinical trials in the state of a rising prostate-specific antigen: Recommendations from the prostate-specific antigen working group . J Clin Oncol . 2004;22:537–556
  24. Russell DW , Wilson JD . Steroid 5 α-reductase: Two genes/two enzymes . Annu Rev Biochem . 1994;63:25–61
  25. Bruchowsky N , Sadar MD , Akakura K , et al.  Characterization of 5 α-reductase gene expression in stroma and epithelium of human prostate . J Steroid Biochem Mol Biol . 1996;59:397–404
  26. Thigpen AE , Silver RI , Guileyard JM , et al.  Tissue distribution and ontogeny of steroid 5 α-reductase isozyme expression . J Clin Invest . 1993;92:903–910
  27. Thomas LN , Douglas RC , Vessey JP , et al.  5-α reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium . J Urol . 2003;170:2019–2025
  28. Clark RV , Hermann DJ , Cunningham GR , et al.  Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 α-reductase inhibitor . J Clin Endocrinol Metab . 2004;89:2179–2184
  29. Roehrborn CG , Boyle P , Nickel JC , et al.  Efficacy and safety of a dual inhibitor of 5-α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia . Urology . 2002;60:434–441
  30. Andriole GL , Humphrey P , Ray P . Effect of the dual 5 α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer . J Urol . 2004;172:915–919
  31. Gleave M , Qian J , Andreou C , et al.  The effects of the dual 5 α-reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month preradical prostatectomy study . The Prostate . 2006;66:1674–1685
  32. Andriole GL . Overview of pivotal studies for prostate cancer risk reduction, past, and present . Urology . 2009;73:S36–S43
  33. Andriole G , Bostwick D , Brawley O , et al.  Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial . J Urol . 2004;172:1314–1317
  34. Andriole G, Bostwick D, Brawley O, et al. Further analyses from the REDUCE prostate caner risk reduction trial. Late Breaking Science Forum (LBA1). Proceedings of the AUA Annual Meeting, Chicago, (IL), April, 2009.
  35. Andriole G , Lieber M , Smith J , et al.  Treatment with finasteride following radical prostatectomy for prostate cancer . Urology . 1995;45:491–497
  36. Schroder FH , Bangma CH , Wolff JM , et al.  Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? (Rationale and design of the Avodart after radical therapy for prostate cancer study) . BJU Int . 2009;103:590–596

☆ Support for this work was provided by the Dominic Ferraioli Foundation and the Bender Scientific Fund of the Community Foundation for the Capital Region.

PII: S1078-1439(10)00007-4

doi: 10.1016/j.urolonc.2010.01.004

Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 2 , Pages 133-138 , March 2012

Article Tools